Developer docs
API playgroundTry for free, no card

Search company profiles

Smartlens

Full company profile

uuid0000kwc

Namestring
Smartlens
Legal namestring
Smartlens, Inc.
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
glaucoma monitoring devices, intraocular pressure sensors, microfluidic contact lens, ophthalmic diagnostics, anterior segment imaging
Industry5 codes
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices / Glaucoma Monitoring
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1miLens Contact Lens Hardware
TypeHardware Sales
Description

Sale of the miLens electronics-free contact lens device for continuous IOP monitoring. The non-invasive device is designed for glaucoma patients requiring diurnal pressure monitoring.

glance.eyesoneyecare.com
2miLens IQ+ Analytics Subscription
TypeSubscription Recurring
Description

AI/ML-powered analytics platform that integrates with miLens and imaging data to provide real-time risk stratification and data-driven analysis for treatment decisions. Likely subscription-based model for continuous access to analytics.

smartlens.health
3THERx IQ Medication Delivery Platform
TypeHardware Sales
Description

Automated micro-dose medication delivery device with programmable treatment timing. Revenue from device sales and potentially refills/replacements of medication cartridges.

smartlens.health
4Anterior Segment Platform Services
TypeSubscription Recurring
Description

AI-powered remote examination platform providing telemedicine capabilities for anterior segment disease assessment. Revenue from platform access/subscription for eyecare practitioners.

smartlens.health
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1miLens
Description

World's smallest wearable microfluidic device for continuous intraocular pressure (IOP) monitoring in glaucoma patients. Electronics-free contact lens designed for diurnal monitoring that works with smartphone-based imaging system.

smartlens.health
+4 more records
Core offering1 text field

Smartlens fundamentally develops and sells the miLens electronics-free microfluidic contact lens system for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients, integrated with the miLens IQ+ AI/ML analytics platform and Slit IQ smartphone imaging. The portfolio is expanding into the Smartlens Anterior Segment Platform for AI-powered remote examination of multiple anterior segment conditions and the THERx IQ automated micro-dose medication delivery wearable. Customers are ophthalmologists, eyecare practitioners, and eyecare institutions seeking continuous monitoring, AI-driven risk stratification, and treatment optimization tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 96.2% practitioner adoption intent based on clinical data
+2 more records
Product overview1 text field

Smartlens offers an integrated ophthalmic monitoring and treatment platform comprising four core products: miLens (electronics-free contact lens for continuous 24/7 IOP monitoring), miLens IQ+ (AI/ML-powered analytics platform for risk stratification), Smartlens Anterior Segment Platform (AI-powered remote examination system), and THERx IQ (automated micro-dose medication delivery device). The platform combines microfluidic technology with AI-enhanced diagnostics to enable continuous monitoring, diagnosis, and treatment optimization for anterior segment diseases, moving from episodic office visits to continuous, data-driven care management.

Product and service5 records
1miLens
CategoryContinuous IOP Monitoring Device
Description

The world's smallest wearable microfluidic device and first electronics-free contact lens for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients. Designed for remote use with a smartphone-based imaging system, miLens captures critical diurnal pressure variations missed by quarterly or annual office-based measurements and enables early detection of dangerous IOP spikes. Built for ophthalmologists, glaucoma specialists, optometrists, and eyecare institutions managing glaucoma patients.

2miLens IQ+
CategoryAI Analytics Platform
Description

AI/ML-powered analytics platform that unlocks insights from first-of-its-kind diurnal IOP monitoring and comprehensive imaging data. Integrates pressure patterns from miLens with standardized anterior segment imaging to provide real-time risk stratification, predictive capabilities, and data-driven analysis to inform treatment decisions. Eliminates subjective variability through standardized, quantifiable measurements.

3Smartlens Anterior Segment Platform
CategoryTelemedicine / Remote Examination Platform
Description

AI-powered remote examination platform providing comprehensive monitoring of all anterior segment conditions including Dry Eye, Cataracts, Conjunctivitis, Blepharitis, Episcleritis, Scleritis, Pterygium, Anterior Uveitis, and Trauma. Facilitates telemedicine capabilities and standardizes disease assessment through AI-powered grading and enhanced monitoring, expanding specialist access across geographic barriers.

4THERx IQ
CategoryAutomated Drug Delivery Device
Description

Novel wearable device providing automated personalized micro-dose medication delivery for chronic eye diseases, with initial focus on glaucoma treatment. Addresses poor medication adherence and imprecise dosing through programmable micro-dosing technology that optimizes treatment timing based on each patient's pressure patterns, enhancing therapeutic efficacy while minimizing side effects common with traditional eye drops.

5Slit IQ
CategorySmartphone Imaging Platform
Description

Smartphone-based imaging platform that integrates with miLens for capturing and analyzing eye pressure data and anterior segment imaging. AI-powered to work seamlessly with the miLens contact lens system for comprehensive remote ophthalmic examination.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Developer of a corneal applanation tonometer designed for continuous, in-eye IOP monitoring using a contact lens form factor. CATS represents an emerging player with technical overlap to Smartlens's contact-lens-based IOP monitoring approach.

TypeBroad incumbent
Description

Long-established manufacturer of Goldmann and non-contact tonometers used as the clinical gold standard for IOP measurement. Reichert represents the entrenched incumbent workflow Smartlens must displace or augment.

TypeBroad incumbent
Description

Swiss manufacturer of ophthalmic diagnostic equipment including slit lamps and tonometers. Haag-Streit is an incumbent in the eyecare diagnostics workflow where Smartlens's Slit IQ smartphone imaging platform competes.

TypeBroad incumbent
Description

Global ophthalmic medtech leader with broad glaucoma, cataract, and contact lens portfolios. Alcon is a strategic competitor and potential acquirer with the commercial scale Smartlens would need to reach the full eyecare practitioner market.

TypeBroad incumbent
Description

Public medtech company specializing in MIGS devices and sustained pharmaceutical delivery for glaucoma. Glaukos is a comparable glaucoma-focused commercial medtech and represents a potential strategic acquirer or benchmark for Smartlens's commercial trajectory.

TypeBroad incumbent
Description

Diversified ophthalmic company with glaucoma pharmaceutical, surgical, and contact lens offerings. Bausch + Lomb operates broadly across the glaucoma care continuum that Smartlens is targeting with its integrated platform.

TypeDirect peer
Description

Swiss developer of the Triggerfish, a CE-marked smart contact lens for 24-hour continuous IOP monitoring in glaucoma. Sensimed is the most direct competitor in continuous IOP-monitoring contact lenses, addressing the same clinical use case as Smartlens's miLens.

TypeRegional player
Description

India-based ophthalmic pharmaceutical company expanding into glaucoma therapeutics and diagnostics. Lupin represents a regional player with overlapping interest in the anterior segment and glaucoma management market that Smartlens addresses.

TypeDirect peer
Description

Manufacturer of rebound tonometers (Icare IC100, Icare HOME) used for in-office and self-measured IOP. Icare is a direct competitor offering an alternative point-of-care and home-based IOP measurement paradigm for glaucoma management.

TypeEmerging player
Description

Emerging developer of smart contact lens platforms with embedded electronics for vision and health applications. InWith represents an emerging competitive threat in the smart contact lens category, though with a different technical approach than Smartlens's electronics-free microfluidics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Smartlens

Ophthalmic Medical Devices / Glaucoma Monitoringsmartlens.health

Smartlens firmographics

Firmographics
Name
Smartlens
Legal name
Smartlens, Inc.
Website
https://smartlens.health
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Smartlens industry classification

Industry
Product category
Ophthalmic Medical Devices / Glaucoma Monitoring
NAICS
Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Glaucoma monitoring devices
  • Intraocular pressure sensors
  • Microfluidic contact lens
  • Ophthalmic diagnostics
  • Anterior segment imaging

Where Smartlens is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Markets served

Smartlens business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. miLens Contact Lens Hardware: Sale of the miLens electronics-free contact lens device for continuous IOP monitoring. The non-invasive device is designed for glaucoma patients requiring diurnal pressure monitoring.
  2. miLens IQ+ Analytics Subscription: AI/ML-powered analytics platform that integrates with miLens and imaging data to provide real-time risk stratification and data-driven analysis for treatment decisions. Likely subscription-based model for continuous access to analytics.
  3. THERx IQ Medication Delivery Platform: Automated micro-dose medication delivery device with programmable treatment timing. Revenue from device sales and potentially refills/replacements of medication cartridges.
  4. Anterior Segment Platform Services: AI-powered remote examination platform providing telemedicine capabilities for anterior segment disease assessment. Revenue from platform access/subscription for eyecare practitioners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Smartlens product offering

Product offering

Core offering

Smartlens fundamentally develops and sells the miLens electronics-free microfluidic contact lens system for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients, integrated with the miLens IQ+ AI/ML analytics platform and Slit IQ smartphone imaging. The portfolio is expanding into the Smartlens Anterior Segment Platform for AI-powered remote examination of multiple anterior segment conditions and the THERx IQ automated micro-dose medication delivery wearable. Customers are ophthalmologists, eyecare practitioners, and eyecare institutions seeking continuous monitoring, AI-driven risk stratification, and treatment optimization tools.

Product overview

Smartlens offers an integrated ophthalmic monitoring and treatment platform comprising four core products: miLens (electronics-free contact lens for continuous 24/7 IOP monitoring), miLens IQ+ (AI/ML-powered analytics platform for risk stratification), Smartlens Anterior Segment Platform (AI-powered remote examination system), and THERx IQ (automated micro-dose medication delivery device). The platform combines microfluidic technology with AI-enhanced diagnostics to enable continuous monitoring, diagnosis, and treatment optimization for anterior segment diseases, moving from episodic office visits to continuous, data-driven care management.

Differentiator

Problem solved

Functional benefit

Brands

  • miLens: World's smallest wearable microfluidic device for continuous intraocular pressure (IOP) monitoring in glaucoma patients. Electronics-free contact lens designed for diurnal monitoring that works with smartphone-based imaging system.
  • miLens IQ+
  • THERx IQ
  • Slit IQ
  • Smartlens Anterior Segment Platform

Products and services

  • miLens The world's smallest wearable microfluidic device and first electronics-free contact lens for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients. Designed for remote use with a smartphone-based imaging system, miLens captures critical diurnal pressure variations missed by quarterly or annual office-based measurements and enables early detection of dangerous IOP spikes. Built for ophthalmologists, glaucoma specialists, optometrists, and eyecare institutions managing glaucoma patients.
  • miLens IQ+ AI/ML-powered analytics platform that unlocks insights from first-of-its-kind diurnal IOP monitoring and comprehensive imaging data. Integrates pressure patterns from miLens with standardized anterior segment imaging to provide real-time risk stratification, predictive capabilities, and data-driven analysis to inform treatment decisions. Eliminates subjective variability through standardized, quantifiable measurements.
  • Smartlens Anterior Segment Platform AI-powered remote examination platform providing comprehensive monitoring of all anterior segment conditions including Dry Eye, Cataracts, Conjunctivitis, Blepharitis, Episcleritis, Scleritis, Pterygium, Anterior Uveitis, and Trauma. Facilitates telemedicine capabilities and standardizes disease assessment through AI-powered grading and enhanced monitoring, expanding specialist access across geographic barriers.
  • THERx IQ Novel wearable device providing automated personalized micro-dose medication delivery for chronic eye diseases, with initial focus on glaucoma treatment. Addresses poor medication adherence and imprecise dosing through programmable micro-dosing technology that optimizes treatment timing based on each patient's pressure patterns, enhancing therapeutic efficacy while minimizing side effects common with traditional eye drops.
  • Slit IQ Smartphone-based imaging platform that integrates with miLens for capturing and analyzing eye pressure data and anterior segment imaging. AI-powered to work seamlessly with the miLens contact lens system for comprehensive remote ophthalmic examination.

Quantifiable outcome

  • 96.2% practitioner adoption intent based on clinical data
  • +2 more outcomes

Companies that use Smartlens

Customer profile

Segments3 records

Ideal customer profiles2 records

Smartlens technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Smartlens partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Smartlens competitors and assessment

Company assessment

Emerging players

  • CATS Tonometer (Cornea Health): Developer of a corneal applanation tonometer designed for continuous, in-eye IOP monitoring using a contact lens form factor. CATS represents an emerging player with technical overlap to Smartlens's contact-lens-based IOP monitoring approach.
  • InWith Corp: Emerging developer of smart contact lens platforms with embedded electronics for vision and health applications. InWith represents an emerging competitive threat in the smart contact lens category, though with a different technical approach than Smartlens's electronics-free microfluidics.

Broad incumbents

  • Reichert Technologies (AMETEK): Long-established manufacturer of Goldmann and non-contact tonometers used as the clinical gold standard for IOP measurement. Reichert represents the entrenched incumbent workflow Smartlens must displace or augment.
  • Haag-Streit (Metall Zug Group): Swiss manufacturer of ophthalmic diagnostic equipment including slit lamps and tonometers. Haag-Streit is an incumbent in the eyecare diagnostics workflow where Smartlens's Slit IQ smartphone imaging platform competes.
  • Alcon: Global ophthalmic medtech leader with broad glaucoma, cataract, and contact lens portfolios. Alcon is a strategic competitor and potential acquirer with the commercial scale Smartlens would need to reach the full eyecare practitioner market.
  • Glaukos Corporation: Public medtech company specializing in MIGS devices and sustained pharmaceutical delivery for glaucoma. Glaukos is a comparable glaucoma-focused commercial medtech and represents a potential strategic acquirer or benchmark for Smartlens's commercial trajectory.
  • Bausch + Lomb (Bausch Health): Diversified ophthalmic company with glaucoma pharmaceutical, surgical, and contact lens offerings. Bausch + Lomb operates broadly across the glaucoma care continuum that Smartlens is targeting with its integrated platform.

Direct peers

  • Sensimed: Swiss developer of the Triggerfish, a CE-marked smart contact lens for 24-hour continuous IOP monitoring in glaucoma. Sensimed is the most direct competitor in continuous IOP-monitoring contact lenses, addressing the same clinical use case as Smartlens's miLens.
  • Icare (Icare Finland Oy / Revenio Group): Manufacturer of rebound tonometers (Icare IC100, Icare HOME) used for in-office and self-measured IOP. Icare is a direct competitor offering an alternative point-of-care and home-based IOP measurement paradigm for glaucoma management.

Regional players

  • Lupin Pharmaceuticals: India-based ophthalmic pharmaceutical company expanding into glaucoma therapeutics and diagnostics. Lupin represents a regional player with overlapping interest in the anterior segment and glaucoma management market that Smartlens addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Smartlens social profiles

Digital presence

Smartlens financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Smartlens leadership team

Management profile

Number of profiles

Profiles12 records

Smartlens funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Smartlens M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Smartlens

What does Smartlens do?

Smartlens fundamentally develops and sells the miLens electronics-free microfluidic contact lens system for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients, integrated with the miLens IQ+ AI/ML analytics platform and Slit IQ smartphone imaging. The portfolio is expanding into the Smartlens Anterior Segment Platform for AI-powered remote examination of multiple anterior segment conditions and the THERx IQ automated micro-dose medication delivery wearable. Customers are ophthalmologists, eyecare practitioners, and eyecare institutions seeking continuous monitoring, AI-driven risk stratification, and treatment optimization tools.

Is Smartlens a public or private company?

Smartlens is a private company. It is classified as venture growth investor backed and is currently operating.

When was Smartlens founded?

Smartlens was founded in 2015. It employs 11 to 50 people.

Where is Smartlens based?

Smartlens is headquartered in Sunnyvale, United States, in the North America region.

How does Smartlens make money?

Four revenue lines are on record. miLens Contact Lens Hardware is the primary driver. The others are miLens IQ+ Analytics Subscription, THERx IQ Medication Delivery Platform and anterior Segment Platform Services.

Who are Smartlens's main competitors?

Emerging players on record are CATS Tonometer (Cornea Health) and InWith Corp. Broad incumbents are Reichert Technologies (AMETEK), Haag-Streit (Metall Zug Group), Alcon, Glaukos Corporation and Bausch + Lomb (Bausch Health). Direct peers are Sensimed and Icare (Icare Finland Oy / Revenio Group). Lupin Pharmaceuticals is listed as a regional player.

Does Smartlens have an API?

No public API is recorded for Smartlens.

What industry is Smartlens in?

Smartlens's product category is Ophthalmic Medical Devices / Glaucoma Monitoring. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions). Its NAICS code is 339115 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesQ&A: What’s in the glaucoma treatment pipeline?Dr. James Tsai outlines the current glaucoma treatment pipeline, highlighting clinical trials for devices like Iantrek's CycloPen and drugs from QLARIS Bio and Ophthalmic Therapeutic Innovation aimed at reducing intraocular pressure. The article also notes progress in surgical technologies and the potential near-term FDA approval for SmartLens Inc.'s smart contact lens for continuous eye pressure monitoring.Optometry TimesSmartlens Inc has secured an oversubscribed $6.1M Series A financing roundSmartlens Inc has secured an oversubscribed $6.1 million Series A financing round. The article does not specify the strategic implications or future plans related to this funding.StartupSeekerSmartlens - Funding: $6M+Smartlens, Inc. has raised over $6 million in funding to support the development of miLens, a non-invasive device that continuously monitors intraocular pressure for glaucoma management. The company utilizes its proprietary THERmic technology to deliver personalized microdose treatments based on real-time patient data.PitchBookSmartlens 2025 Company Profile: Valuation, Funding & InvestorsSmartlens is a private company developing a microfluidic-based smart contact lens designed to monitor intraocular pressure and prevent glaucoma progression. The company has secured 11 investors and is preparing for an upcoming Series B funding round valued at $20 million.LinkedInSmartlens, IncSmartlens, Inc. has closed an oversubscribed $5.2 million bridge funding round led by Ambit Health Ventures to advance its miLens technology toward FDA clearance. The miLens is an electronics-free contact lens that continuously monitors intraocular pressure, addressing a critical gap in glaucoma management where traditional methods often miss daily fluctuations.Eyes On EyecareSmartlens raises $5.2 million to advance miLens FDA clearance and launchSmartlens, Inc. secured $5.2 million in an oversubscribed bridge round led by Ambit Health Ventures to advance FDA clearance and prepare for the market launch of its miLens technology. The miLens is a contact lens-based device designed to continuously monitor intraocular pressure for glaucoma patients, utilizing a smartphone imaging platform for data capture. The funding supports ongoing pivotal clinical trials in the United States, with a new prospective trial expected to conclude in February 2026.Eyes On EyecareSmartlens raises $5.2 million to advance miLens FDA clearance and launchSmartlens, Inc. has raised $5.2 million in an oversubscribed bridge round led by Ambit Health Ventures to advance FDA clearance and prepare for market launch of miLens, its electronics-free contact lens technology for continuous intraocular pressure monitoring in glaucoma patients. The miLens integrates with Smartlens's Slit IQ smartphone imaging platform and is currently undergoing pivotal clinical trials across the United States, with a new 125-patient trial (NCT06689696) expected to conclude in February 2026. The funding follows a prior $6.1 million round in 2023 and builds on positive 2023 clinical data showing strong correlation between miLens and Goldmann tonometer measurements.ClspectrummiLens Nears Market with New FundingSmartlens Inc. has closed a $5.2 million bridge financing round led by Ambit Health Ventures to support the FDA clearance and commercial launch of its miLens contact lens platform. The funding will aid in regulatory preparation, manufacturing scale-up, and clinical validation for the device, which monitors intraocular pressure for glaucoma patients. An independent survey indicated that 96.2% of ophthalmic practitioners intend to adopt the technology upon availability.LeadsontreesSmartlens, Inc. Secures $5.2M to Transform Eye CareSmartlens, Inc. has secured $5.2 million in a recent funding round aimed at transforming eye care through innovative monitoring and treatment technologies. This investment reflects strong investor confidence in the company's mission to enhance disease management for conditions like glaucoma, with a comprehensive platform slated for commercialization in 2026.TechStartupsSmartlens raises $5.2M in funding to revolutionize glaucoma care with world’s first electronics-free smart contact lensSmartlens, a Silicon Valley-based startup, has secured $5.2 million in an oversubscribed bridge round led by Ambit Health Ventures to advance its FDA clearance and commercial launch for miLens, an electronics-free smart contact lens. The device continuously monitors intraocular pressure to aid in glaucoma management, supported by an AI-powered smartphone imaging platform that provides actionable insights to ophthalmologists. This funding aims to accelerate regulatory approval following encouraging results from multi-site U.S. pivotal trials.